Haloperidol, racilopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not

Psychopharmacology

Volumn 140, Issue 1, 1998, Pages 81-90

  Fowler, Stephen C ^a   Liou, Jiing Ren ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic drug; Catalepsy; Dopamine receptor; EPS; Neuroleptics; Rat

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ATROPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; ETICLOPRIDE; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RACLOPRIDE; SCOPOLAMINE; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; SPRAGUE DAWLEY RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; CLOZAPINE; CONDITIONING, OPERANT; HALOPERIDOL; MALE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; SALICYLAMIDES;

EID: 0031593778     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050742     Document Type: Article

References (53)

1. Ahlenius S (1991) Pharmacological evaluation of new antipsychotic drugs. In: Willner P (ed) Behavioural models in psychopharmacology: theoretical, industrial, and clinical perspectives. Cambridge University Press, Cambridge, Mass., pp 311-330
2. Ahlenius S, Ericson EL, Hogberg K, Wijkstrom A (1991) Behavioral and biochemical effects of subchronic treatment with raclopride in the rat: tolerance and brain monoamine receptor sensitivity. Pharmacol Toxicol 68:302-309
3. Baldessarini RJ (1996) Drugs and the treatment of psychiatric disorders: psychosis and anxiety In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) Goodman & Gilman's the pharmacological basis of therapeutics (9th edn). McGraw-Hill, New York, pp 399-430
4. Barnes DE, Robinson B, Csernansky JG, Bellows EP (1990) Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 36:883-887
5. British Isles Raclopride Study Group (1992) A double blind comparison of raclopride and haloperidol in the active phase of schizophrenia. The British Isles Raclopride Study Group. Acta Psychiatr Scand 86:391-398
6. Brockel BJ, Fowler SC (1995) Effects of chronic haloperidol on reaction time and errors in a sustained attention task: partial reversal of effects by anticholinergics and by amphetamine. J Pharmacol Exp Ther 275:1090-1098
7. Casey DE (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112 [1 Suppl]:S55-59
8. Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58 [suppl 10]:55-62
9. 1 receptors. J Pharmacol Exp Ther 249:769-774
10. Costall B, Naylor RJ (1975) Detection of the neuroleptic properties of clozapine, sulpiride, and thioridazine. Psychopharmacologia 43:69-74
11. Delfs JM, Anegawa NJ, Chesselet MF (1995) Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience 66:67-80
12. Ellenbroek BA, Peeters BW, Honig WM, Cools AR (1987) The paw test: a behavioral paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 93:343-348
13. Essig EC, Kilpatrick IC (1991) Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology 104:194-200
14. Ford KE, Fowler SC, Nail GL (1979) Effects of clozapine and chlorpromazine upon operant response measures in rats. Pharmacol Biochem Behav 11:239-241
15. Fowler SC, Kirkpatrick MA (1989) Behavior-decrementing effects of low doses of haloperidol result from disruptions in response force and duration. Behav Pharmacol 1:123-132
16. 2 (raclopride) antagonists. Psychopharmacology 115:24-30
17. Fowler SC, LaCerra MM, Ettenberg A (1986) Effects of haloperidol on the biophysical characteristics of operant responding: implications for motor and reinforcement processes. Pharmacol Biochem Behav 25:791-796
18. Fowler SC, Liao R-M, Skjoldager PD (1990) A new rodent model for neuroleptic-induced pseudoparkinsonism: low doses of haloperidol increase forelimb tremor in the rat. Behav Neurosci 104:449-456
19. Fowler SC, Skjoldager PD, Liao R-M, Chase JM, Johnson JS (1991) Distinguishing between haloperidol's and decamethonium's disruptive effects on operant behavior in rats: use of measurements that complement response rate. J Exp Anal Behav 56:239-260
20. Fowler SC, Davison KH, Stanford JA (1994) Unlike haloperidol, clozapine slows and dampens rats' forelimb force oscillations and decreases force output in a press-while-licking behavioral task. Psychopharmacology 116:19-25
21. Gallup GG, Maser JD (1977) Tonic immobility: evolutionary underpinnings of human catalepsy and catatonia. In: Maser JD, Seligman MEP (eds) Psychopathology: experimental models. Freeman, San Francisco, pp 334-357
22. 2, and muscarinic acetylcholine receptor occupancies. Drug Metab Dispos 25:675-684
23. Hillegaart V, Ahlenius S (1987) Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol, and preclamol. Pharmacol Toxicol 60:350-354
24. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal effects. Psychopharmacology 120:128-133
25. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopamine systems. J Pharmacol Exp Ther 226:462-468
26. 2 antagonists on a conditioned avoidance task in rats. J Pharmacol Exp Ther 258:118-123
27. Kiritsy-Roy JA, Standish SM, Terry LC (1989) Dopamine D-1 and D-2 receptor antagonists potentiate analgesic and motor effects of morphine. Pharmacol Biochem Behav 32:717-721
28. Klemm WR (1983) Cholinergic-dopaminergic interactions in experimental catalepsy. Psychopharmacology 81:24-27
29. Klemm WR (1989) Drug effects on active immobility responses: what they tell us about neurotransmitter systems and motor functions. Prog Neurobiol 32:403-422
30. Lappalaienen J, Hietala J, Syvalahti E (1989) Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology 98:472-475
31. 2 receptors. Psychopharmacology 112 [Suppl]:S40-S54
32. 2 receptor antagonist, raclopride, in Cebus monkeys withdrawn from previous haloperidol treatment: extrapyramidal syndromes and dopaminergic supersensitivity. Psychopharmacology 112:389-397
33. 2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45:195-200
34. 2 dopamine receptor antagonists produce differential effects on reaction time in the rat. Pharmacol Biochem Behav 46:759-768
35. McMillan DE, Leander JD (1976) Effects of drugs on schedule-controlled behavior. In: Glick SD, Goldfarb J (eds) Behavioral pharmacology. Mosby, St Louis, Mo., pp 85-139
36. Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 1-13
37. Morelli M, Di Chiara G (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117:179-185
38. Newman-Tancredi A, Audinot V, Chaput C, Verriele L, Millan MJ (1997) [35 S]Guanosine-5′-O-(3thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191
39. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294
40. Ohman R, Larsson M, Nilsson IM, Engel J, Carlsson A (1977) Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Sehmiedeberg's Arch Pharmacol 299:105-114
41. Osborne PG, O'Connor WT, Beck O, Ungerstedt U (1994) Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine. GABA and acetylcholine release. Brain Res 634:20-30
42. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
43. Sanberg PR, Pisa M, Faulks IJ, Fibiger, HC (1980) Experimental influences on catalepsy. Psychopharmacology 69:225-226
44. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748-759
45. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947-950
46. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, DeLoore K, Leysen J (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73
47. 2 receptor selectivities of agonists and antagonists. Adv Exp Med Biol 235:55-63
48. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
49. Sovner R, DiMascio A (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1021-1032
50. Stanford JA, Fowler SC (1997) Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness. Psychopharmacology 132:408-414
51. Wilkinson, L (1990) SYSTAT: the system for statistics. SYSTAT, Evanston, III.
52. Weiss B, Santelli S, Lusink G (1977) Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology 53:289-293
53. 1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528-8535